Sun Pharma Advanced Research Company Limited (SPARC)

Loading page…

Sun Pharma Advanced Research Company Limited (SPARC) · mywealthgrid

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	76	72	1,879
COGS	28	23	24
Gross profit	47	49	1,856
	450	372	257
	-402	-323	1,599
OPM %	-532.2%	-450.2%	85.1%
Depreciation	13	12	10
Interest	2	9	34
	29	2	-1
Profit before tax	-387	-343	1,553
Tax	0	-0	-0
Tax %	0.1%	-0.1%	-0%
PAT	-387	-343	1,553
PAT margin %	-512.5%	-477.2%	82.7%
EPS (₹)	-11.9	-10.6	47.9
EPS adjusted (₹)	-11.9	-10.6	47.9
Annual report	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	32	32	32	32
Reserves	—	93	-249	1,306
	—	47	258	556
	—	342	294	276
Total equity & liabilities	—	515	336	2,171
	106	108	99	85
CWIP	—	1	1	1
Investments	—	2	0	0
	—	404	236	2,085
Total assets	—	515	336	2,171

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-69	-429	-360	-239
	-548	392	158	-24
	617	42	199	261
Net cash flow	-1	5	-3	-1
Free cash flow	—	-456	-371	-263
CFO / Operating profit %	—	—	—	-14.9%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 2,518%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 116%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	62.8%	67.8%	98.7%
EBITDA margin %	-532.2%	-450.2%	85.1%
EBIT margin %	-548.8%	-467.5%	84.5%
PAT margin %	-512.5%	-477.2%	82.7%
Working capital
Receivable days	75	82	2
Inventory days	0	0	0
Payable days	1,846	1,798	1,503
NWC days	-1,771	-1,717	-1,501
Leverage
Current ratio	1.02	0.07	2.47
Debt to EBITDA	—	—	0.35
Debt to equity	0.37	-1.19	0.42
Interest coverage	-227.9	-36.9	46.9
Asset turnover	0.15	0.21	0.87
Return ratios
Return on assets %	-75.2%	-102.1%	71.5%
Return on capital employed %	-154.1%	-315.9%	112.9%
Return on equity %	-307.9%	157.9%	116%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%	65.67%
	3.67%	3.3%	3.23%	2.64%	2.15%	2.23%	1.45%	1.47%	1.76%	2.04%	2.04%	3.9%
	0.8%	0.81%	0.82%	0.18%	0.23%	0.64%	1.13%	0.97%	1.05%	0.78%	0.88%	0.09%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	29.86%	30.22%	30.28%	31.51%	31.95%	31.46%	31.75%	31.89%	31.52%	31.51%	31.41%	30.34%
No. of shareholders	—	—	—	—	—	—	—	—	1,36,997	1,44,810	1,40,625	1,41,957

Promoter holding up 0 percentage points since Sep 2023.

59 deals · 19 Sept 2022 – 26 May 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
26 May 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	19,86,488	₹240.53	₹47.78 Cr
26 May 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	18,95,932	₹240.86	₹45.67 Cr
25 May 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	25,32,120	₹226.90	₹57.45 Cr
25 May 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	24,20,817	₹227.49	₹55.07 Cr
25 May 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	23,96,273	₹227.61	₹54.54 Cr
25 May 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	23,63,979	₹226.35	₹53.51 Cr
25 May 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	22,17,270	₹227.43	₹50.43 Cr
25 May 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	22,17,270	₹227.54	₹50.45 Cr
25 May 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	21,28,865	₹228.38	₹48.62 Cr
25 May 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	21,28,865	₹228.31	₹48.60 Cr

1–10 of 59

1 / 6

Mr. Dilip Shantilal ShanghviNon-Executive - Non Independent Director-Chairperson related to Promoter
Ms. Vidhi Dilip ShanghviNon-Executive - Non Independent Director
Mr. Anil RaghavanExecutive Director & Chief Executive Officer
Mr. Robert SpiegelNon-Executive - Independent Director
Mr. Venkateswarlu JastiNon-Executive - Independent Director
Ms. Rekha Gopal WarriarNon-Executive - Independent Director
Ms. Kajal DamaniaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 3 fund houses

Held by these funds

0.09%

of the company's equity

All mutual funds

0.08%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

5 schemes · 3 fund houses

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	2.45 L	4.88	0.2%	0.075%	-5,363
MULTI CAP FUND	Samco Mutual Fund	47,421	0.95	0.41%	0.015%	+8,669
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	2,582	0.05	0.12%	0.001%	+4
IB18-Groww Nifty Total Market Index Fund	Groww Mutual Fund	1,676	0.03	0.01%	0.001%	+7
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	279	0.01	0.01%	0%	-0

Loading fund holders…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

15 announcementsExport CSV

11 Aug 2026, 11:55 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

10 Aug 2026, 7:47 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

10 Aug 2026, 2:56 pmCompany Update

Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Monitoring Agency Report PDF

10 Aug 2026, 1:33 pmResult

Unaudited Financial Results For The Quarter Ended June 30, 2026

Financial Results PDF

10 Aug 2026, 1:28 pmBoard Meeting

Board Meeting Outcome for Outcome Of The Board Meeting

Outcome of Board Meeting PDF

3 Aug 2026, 3:05 pmBoard Meeting

Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026

Exchange filing PDF

27 Jul 2026, 6:26 pmCompany Update

Intimation For Receipt Of Requests For Reclassification Of Shareholder Category

General PDF

17 Jul 2026, 12:14 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
11 Aug 2026, 11:55 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
10 Aug 2026, 7:47 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM

Loading announcements…

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	62.8%	67.8%	98.7%
EBITDA margin %	-532.2%	-450.2%	85.1%
EBIT margin %	-548.8%	-467.5%	84.5%
PAT margin %	-512.5%	-477.2%	82.7%
Working capital
Receivable days	75	82	2
Inventory days	0	0	0
Payable days	1,846	1,798	1,503
NWC days	-1,771	-1,717	-1,501
Leverage
Current ratio	1.02	0.07	2.47
Debt to EBITDA	—	—	0.35
Debt to equity	0.37	-1.19	0.42
Interest coverage	-227.9	-36.9	46.9
Asset turnover	0.15	0.21	0.87
Return ratios
Return on assets %	-75.2%	-102.1%	71.5%
Return on capital employed %	-154.1%	-315.9%	112.9%
Return on equity %	-307.9%	157.9%	116%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Sun Pharma Advanced Research Company Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Compounded sales growth

Return on equity

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

1

Announcements

1

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Compounded sales growth

Return on equity

Sun Pharma Advanced Research Company Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1